Sign in
4

Changes in Ownership

ArriVent BioPharma, Inc. Filed Acc 0001104659-25-067928

Chief Operating Officer acquired 11,153 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
LaChapelle Robin Chief Operating Officer 2025-07-11 Option exercise +2,050 $2.28 $4,674 126,633 D: show line 1 in the form
LaChapelle Robin Chief Operating Officer 2025-07-11 Option exercise +2,600 $2.28 $5,928 129,233 D: show line 2 in the form
LaChapelle Robin Chief Operating Officer 2025-07-11 Option exercise +6,503 $2.28 $14,827 135,736 D: show line 3 in the form

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
LaChapelle Robin Chief Operating Officer 2025-07-11 Option exercise · Stock Option (right to buy) −2,050 410 D: show line 4 in the form
LaChapelle Robin Chief Operating Officer 2025-07-11 Option exercise · Stock Option (right to buy) −2,600 12,873 D: show line 5 in the form
LaChapelle Robin Chief Operating Officer 2025-07-11 Option exercise · Stock Option (right to buy) −6,503 6,370 D: show line 6 in the form
Loading xslF345X05/tm2520948-1_4seq1.xml…